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ABSTRACT 
The purpose of this study was to clarify the effects of oxaliplatin on the function and 
expression of the multidrug efflux transporter P-glycoprotein/MDR1 in a porcine kidney 
epithelial cell line, LLC-PK1, as a renal tubular epithelial model. LLC-PK1 cells were 
pretreated with or without oxaliplatin for 48 h, and the growth inhibitory effects of a 
MDR1 substrate, paclitaxel, and the transport of a MDR1 substrate, Rhodamine123, 
were assessed. The level of MDR1 mRNA and protein was also examined in the cells 
treated with or without oxaliplatin for 48 h using RT-PCR and immunoblotting. In the 
present study, the pretreatment with oxaliplatin tended to suppress the growth inhibitory 
effects of paclitaxel in LLC-PK1 cells, presumably by accelerating the functions of 
MDR1. In addition, the uptake of Rhodamine123 was reduced significantly by 
pretreatment with oxaliplatin, and the efflux of Rhodamine123 from LLC-PK1 cells was 
enhanced significantly. These accelerated functions were supported by the suppression 
of Rhodamine123’s transport by a representative MDR1 substrate/inhibitor, ciclosporin, 
at 10 μM. The exposure to oxaliplatin for 48 h resulted in an increase in the expression 
of MDR1 in LLC-PK1 cells. These findings were similar to those obtained with cisplatin, 
a nephrotoxic drug. In conclusion, the present findings suggested that transient exposure 
for 48 h to oxaliplatin caused the up-regulation of MDR1 function and expression in 
LLC-PK1 cells, as was the case for cisplatin. 
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INTRODUCTION 
 
Oxaliplatin, an antitumor platinum 
complex first synthesized by Kidani et al. 
(1980), shows a stronger antitumor 
activity against various colon cancer cell 
lines than its analogues, cisplatin and 
carboplatin (Armand et al., 2000). 
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Oxaliplatin has been used for the 
treatment of metastatic colorectal cancer 
in combination with fluoropyrimidines in 
Europe, the USA and Asia, and its clinical 
efficacy has been confirmed (de Gramont 
et al., 2000; Fakih 2004). In 2005, 
oxaliplatin was also approved for use in 
Japan, where over four thousands patients 
have been treated with it. Oxaliplatin has a 
characteristic side effect, i.e., sensory 
neurotoxicity, however, it is less 
nephrotoxic than cisplatin (Cassidy and 
Misset 2002). 
 
Multidrug resistance (MDR) is one of the 
major causes of failure in cancer 
chemotherapy (Takara et al., 2006a). The 
mechanism involved is considered to be 
an acceleration of efflux, and 
P-glycoprotein/MDR1, belonging to the 
ATP-Binding Cassette (ABC) superfamily, 
has especially attracted attention 
(Bradshaw and Arceci 1998). MDR1 has 
been shown to act as an efflux pump to 
remove anticancer drugs, resulting in a 
decrease in their cellular concentration to 
below the lethal level. In addition, MDR1 
was clarified to be expressed in the apical 
membrane of normal tissues including the 
liver, kidneys, intestine, and brain (Borst 
et al., 1993; Fojo et al., 1987; Kusuhara et 
al., 1998; Thiebaut et al., 1987). Recently, 
MDR1 was also demonstrated to 
participate in the control of apoptosis 
(Huang et al., 2001; Johnstone et al., 
2000; Sakaeda et al., 2002; Smyth et al., 
1998). Thus, MDR1 is considered to be a 
regulatory factor for maintaining 
homeostasis, being involved in protection 
against various types of toxins and stress. 
Previously, we have examined whether 
MDR1-dependent protection was 
activated under cytotoxic conditions 
induced by cisplatin, a nephrotoxic 
anticancer drug that is not a substrate for 
MDR1 (Takara et al., 2003a). The study 
demonstrated that transient exposure to 
cisplatin caused up-regulation of the 
function and expression of MDR1 in 
porcine kidney epithelial LLC-PK1 cells 
as a model of renal tubular cells. This 
suggests that changes in the function and 
expression of MDR1 are one of the factors 
protecting against the nephrotoxicity of 
cisplatin. 
 
Herein, the effects of oxaliplatin on the 
function and expression of MDR1 were 
examined in a porcine kidney epithelial 
cell line, LLC-PK1, as a model of renal 
tubular cells. In addition, the findings 
obtained were compared with those for 
cisplatin. 
 
MATERIALS AND METHODS 
 
Chemicals 
Oxaliplatin was purchased from 
Sigma-Aldrich Chemical Co. (St. Louis, 
MO, USA). Paclitaxel and ciclosporin 
(CsA) were obtained from Wako Pure 
Chemical Industries, Ltd. (Osaka, Japan). 
WST-1 and 1-methoxy PMS were 
purchased from Dojindo Laboratories 
(Kumamoto, Japan). Rhodamine123 was 
obtained from Molecular Probes, Inc. 
(Eugene, OR, USA). 
 
Cells and cell culture 
The porcine kidney epithelial LLC-PK1 
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cells (220-232 passages) were maintained 
in a culture medium consisting of Medium 
199 (Invitrogen Corp., GrandIland, NY, 
USA) supplemented with 10% fetal 
bovine serum (Lot No. 99H2314, 
Sigma-Aldrich) without antibiotics. 
LLC-PK1 cells (1.0 x 106) were seeded, 
and grown in a humidified atmosphere of 
5% CO2-95 % air at 37°C, being passaged 
every 3 or 4 days with 0.02% 
EDTA-0.05% trypsin solution 
(Invitrogen). 
 
Growth inhibition assay 
The cytotoxicity of paclitaxel, a substrate 
for MDR1, was evaluated in LLC-PK1 
cells pretreated with oxaliplatin by using a 
WST-1 colorimetric assay (Takara et al., 
2002a, 2005). LLC-PK1 cells were 
pretreated with or without 0.1 or 1 µM 
oxaliplatin for 48 h, and then the cells 
(5,000 cells/well) were re-seeded into 
96-well plates (Corning Inc., NY, USA) in 
100 µL of culture medium without 
paclitaxel on Day 0, and 24 h later the 
culture medium was exchanged for one 
containing paclitaxel (on Day1). After 3 
days at 37°C, the WST-1 colorimetric 
assay was performed (on Day 4). The 
culture medium was exchanged for one 
containing WST-1 reagent solution, and 
3h later, the absorbance was determined at 
450 nm with a reference wavelength of 
620 nm using a SpectraFluor microplate 
reader (Tecan Seetrasse, Switzerland). The 
50% growth inhibitory concentration 
(IC50) of paclitaxel in LLC-PK1 cells was 
calculated according to the sigmoid 
inhibitory effect model; E=Emax×  [1－
Cγ/(Cγ+IC50γ)], by means of a nonlinear 
least-squares method (Solver, Microsoft 
Excel 2001). E and Emax represent the 
surviving fraction (% of control) and its 
maximum, respectively, and C and γ 
represent the drug concentration in the 
medium (nM) and the sigmoidicity factor, 
respectively. 
 
Transport of Rhodamine123 
The uptake of Rhodamine123, a substrate 
for MDR1, was determined as described 
previously (Takara et al., 2002b, 2003a, 
2003b). LLC-PK1 cells (5.0 x 104 
cells/well) were seeded into 24-well plates, 
and incubated for 48 h in a humidified 
atmosphere of 5% CO2-95% air at 37°C. 
Then, the culture medium was exchanged 
for a fresh culture medium containing 0.1, 
1 or 10 µM oxaliplatin, and further 
incubated for 48 h in a humidified 
atmosphere of 5% CO2-95% air at 37°C. 
After pretreatment with oxaliplatin, cells 
were washed twice with a warmed Hanks’ 
balanced salt solution (HBSS), and the 
uptake experiments were started by 
addition of fresh HBSS containing 10 µM 
Rhodamine123 with or without 10 µM 
ciclosporin (CsA), which is a 
representative substrate/inhibitor for 
MDR1. CsA was used in order to clarify 
the contribution of MDR1 to the transport 
of Rhodamine123. The reaction was 
stopped by aspiration of HBSS from the 
wells, followed by washing three times 
with ice-cold phosphate buffered saline 
(PBS). 
 
In the efflux experiments, LLC-PK1 cells 
were cultured in the same manner as 
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described for the uptake experiments. 
Cells were washed twice with warmed 
HBSS and incubated in fresh HBSS 
containing 10 µM Rhodamine123 with or 
without 10 µM CsA for 1 h (Loading 
time). After loading, HBSS was removed 
immediately from the wells and cells were 
washed twice with ice-cold HBSS. Efflux 
experiments were started immediately by 
addition of warmed HBSS excluding 
Rhodamine123 with or without 10 µM 
CsA, and further incubated for 1 h at 37°C. 
The reaction was stopped by aspiration of 
HBSS from the wells, followed by 
washing three times with ice-cold PBS. 
 
After finishing the transport experiments, 
cells were lysed with 0.3 M NaOH, and 
neutralized with an equal volume of 0.3 M 
HCl. Aliquots (200 µL) of cell lysate were 
transferred into 96-well black plates, and 
the fluorescence intensity of 
Rhodamine123 was measured using the 
SpectraFluor (Tecan) with an excitation 
wavelength of 485 nm and emission 
wavelength of 535 nm. Protein content 
was determined by the method of Lowry 
(Lowry et al., 1951), and bovine serum 
albumin was used as the standard. 
 
RT-PCR analysis of MDR1 mRNA 
LLC-PK1 cells (1.0 x 106) were seeded on 
plastic culture dishes, and incubated for 
48 h. The culture medium was exchanged 
for that containing oxaliplatin at the 
indicated concentrations, and further 
incubated at 37°C for 48 h. Total RNA 
was isolated using a GeneElute™ 
Mammalian Total RNA Miniprep kit 
(Sigma-Aldrich) and aliquots (0.75 µg) of 
RNA were used for reverse transcription 
and cDNA-PCR, using an RNA PCR kit 
(AMV) version 2.1 (TakaraBio Inc., Shiga, 
Japan). The PCR oligonucleotide primers 
for amplification of MDR1 and β-actin 
(BA) cDNA were synthesized by Proligo 
Japan K.K. (Kyoto, Japan) and their 
sequences were shown in a previous 
report (Takara et al., 2003a, 2006b). 
 
PCR amplification was initiated by one 
cycle at 94°C for 2 min followed by 35 
(MDR1) or 25 (BA) sequential cycles of 
denaturation at 94°C for 45 sec, annealing 
at 60°C for 45 sec, and extension at 72°C 
for 45 sec in a thermal cycler (BioRad 
Laboratories, Inc., CA, USA). PCR 
products were separated on 
Tris-acetate-EDTA 3% agarose gels 
containing ethidium bromide. 
Densitometric analysis was performed on 
a Macintosh computer using NIH Image 
ver.1.63 (National Institutes of Health, 
Bethesda, MD, USA), and the ratios of 
band intensity (MDR1/BA) were 
calculated. 
 
Western blot analysis 
Cells were cultured and treated with the 
protocol mentioned above. After the 
treatment, cells were harvested and lysed 
with CelLytic™-M (Sigma-Aldrich) and 
centrifuged at 10,000 rpm (9,100 g) at 4°C 
for 15 min. The supernatant was collected, 
and the total protein content was 
determined according to the Bradford 
method (Bradford 1976) using bovine 
γ-globulin as the standard.
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Table 1: IC50 values for paclitaxel in LLC-PK1 cells pretreated with or 
without oxaliplatin for 48 h 
Treatment IC50 (nM) RRa) 
Control 2.33 ± 0.31 － 
+ 0.1 µM oxaliplatin 3.52 ± 1.12 1.51 
+ 1 µM oxaliplatin 4.96 ± 0.50 2.13 
Cells were pretreated with or without oxaliplatin (0.1 and 1 µM) for 48 
h at 37°C, and then the cytotoxic effect of paclitaxel for 72 h was 
evaluated by a WST-1 assay. Each IC50 value represents the mean ± 
SEM for four independent experiments. a) Relative resistance; the IC50 
value in the pretreated cells was divided by that in the control. 
An aliquot of protein (20 or 10 µg) was 
loaded in each lane to detect the 
expression of MDR1 or BA, respectively, 
electrophoresed on a 7.5% 
SDS-polyacrylamide gel by the method of 
to a polyvinylidene difluoride (PVDF) 
membrane Immun-Blot™ (pore size 0.2 
µm, Bio-Rad). For immunoblotting, the 
membranes were blocked with 5% skim 
milk (Wako) in PBS-T (80 mM Na
Laemmli (Laemmli 1970), and transferred 20 mM NaH2PO4, 137 mM NaCl and 
2HPO4, 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Uptake of Rhodamine123 in LLC-PK1 cells pretreated with oxaliplatin
for 48 h. Cells were pretreated with (closed symbol) or without (open circle)
oxaliplatin at 0.1 (  ), 1 (  ), or 10 µM (  ) for 48 h at 37°C, and then the 
accumulation of Rhodamine123 (10 µM) was evaluated for the periods indicated 
at 37°C. Each point represents the mean ± SEM for three independent 
experiments. * and ** p<0.05 and 0.01 significantly different from the un-treated 
groups at the corresponding time points, respectively. Each point in the 
pre-treated cells at 5 min was also significantly different (p<0.01) from the 
control. 
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0.1% Tween 20) at 37°C for 1 h. The blots 
were incubated with anti-MDR1 
monoclonal antibody C219 (1:200, Zymed 
Laboratories Inc., South San Francisco, 
CA, USA) or anti-BA monoclonal 
antibody (1:5,000, Sigma-Aldrich) for 2 h, 
then with horseradish peroxidase 
(HRP)-linked whole sheep antibody to 
mouse IgG (NA931, Amersham 
Biosciences) as a secondary antibody for 1 
h, and washed five times with PBS-T. 
Except where stated specifically, all 
washing and incubation steps were 
performed at ambient temperature. MDR1 
and BA were detected with the HRP 
chemiluminescent reaction (ImmobilonTM 
Western Chemiluminescent HRP 
Substrate, Millipore Corp., Billerica, MA, 
USA) according to the manufacturer’s 
instructions. Blots were then exposed to a 
Polaroid film using an ECL Mini-Camera 
(Amersham Biosciences). 
Statistical analysis 
Comparisons between two groups were 
unpaired Student t-test 
TS 
Growth inhibit f paclitaxel in 
xaliplatin-pretreated cells 
paclitaxel, a 
performed with the 
(transport experiments). In the case of 
more than three groups, the one-way 
analysis of variance (ANOVA) followed 
by the Dunnett test (transport experiments 
and mRNA expression) was used. A p 
value of less than 0.05 (two-tailed) was 
considered significant. 
 
RESUL
 
ory effects o
o
Table 1 shows the 50% growth inhibitory 
concentration (IC50) for 
MDR1 substrate, in LLC-PK1 cells 
pretreated with or without oxaliplatin for 
48 h. 
 
 
Table 2: Effects of ciclosporin (CsA) on the cellular accumulation of Rhodamine123 
for 2 h in LLC-PK1 cells pretreated with or without oxaliplatin 
 Cellular accumulation 
(nmol/mg protein/2 h) 
 Absence of CsA Presence of CsA 
Fold 
increasea) 
LLC-PK1 1.22 ± 0.07 2.82 ± 0.31* 2.32 
+ 0.1 µM oxaliplatin 1.33 ± 0.02 2.92 ± 0.12** 2.20 
+ 1 µM oxaliplatin 0.98 ± 0.03 2.71 ± 0.15** 2.77 
+ 10 µM oxaliplatin 0.59 ± 0.03 1.18 ± 0.01** 1.99 
Cells were pretreated with or without oxaliplatin (0.1, 1, or 10 µM) for 48 h at 37°C,
and then the accumulation of Rhodamine123 (10 µM) for 2 h was evaluated in the 
absence or presence of 10 µM ciclosporin (CsA). Each value represents the mean ±
SEM for three independent experiments. * and ** p<0.05 and 0.01 significantly 
different from the respective group in the absence of CsA, respectively. a) The 
cellular accumulation of Rhodamine123 in the presence of CsA was divided by the 
respective value in the absence of CsA. 
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The IC50 value for paclitaxel in LLC-PK1 
ransport activity of MDR1 using 
of Rhodamine123 was 
 
s 
ignificantly increased by the addition of 
hodamine123 at 1 h decreased 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Rhodamine123 efflux for 1 h in LLC-PK1 cells pretreated with o
cells increased in a 
concentration-dependent manner on 
pretreatment with oxaliplatin for 48 h, 
resulting in decrease in the sensitivity to 
the MDR1 substrate. 
 
T
Rhodamine123 
The uptake 
examined in LLC-PK1 cells pretreated 
with or without oxaliplatin for 48 h (Fig. 
1). The uptake was reduced significantly 
by pretreatment with oxaliplatin in a 
concentration-dependent manner. Also,  
the cellular accumulation for 2 h wa
s
10 µM ciclosporin (CsA), a representative 
substrate/inhibitor for MDR1, and 
recovered to the level found in LLC- PK1 
cells, the effect in the cells pre-treated 
with 10 µM oxaliplatin was low (Table 2). 
 
The residual cellular amounts of 
R
significantly dependent on the 
concentration of oxaliplatin (Fig. 2). The 
effluxes were significantly restored with 
the addition of 10 µM CsA, although it 
was low in the case of 10 µM oxaliplatin. 
r 
without oxaliplatin for 48 h and their alterations by ciclosporin (CsA). Cells were
pretreated with or without oxaliplatin (0.1, 1 and 10 µM) for 48 h at 37°C, and
then the efflux of Rhodamine123 was evaluated for 1 h in the absence or
presence of 10 µM ciclosporin (CsA). Each bar represents the mean ± SEM of
three independent experiments. * and ** p<0.05 and 0.01 significantly different
from the control in the absence of CsA, respectively. †† p<0.01 significantly 
different from the respective group in the absence of CsA. 
0
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Figure 3: Effects of oxaliplatin on MDR1 expression in LLC-PK1 cells. Cells were 
treated with or without the indicated concentrations of oxaliplatin for 48 h at 37°C
(a) Total RNA was extracted from cells, and MDR1 and BA mRNA expression 
was evaluated by RT-PCR. A representative electrophoretogram is presented, 
and BA represents an internal standard gene. (b) Data are presented as a 
percentage of the MDR1/BA mRNA level in LLC-PK1 cells. Each bar represents 
the mean ± SEM for four independent experiments. * p<0.05 significantly 
different from the control. (c) Total protein was extracted from cells, and
electrophoresed on a 7.5% SDS-polyacrylamide gel. For immunoblotting, the 
blots were incubated with anti-MDR1 (C219) or anti-βactin (BA) antibodies. A 
representative immunoblot is presented, and BA was used as the reference 
protein. 
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USSION 
Pretreatment  for 48 h 
nded to suppress the growth inhibitory 
expression in LLC-PK1 cells were 
examined using RT-PCR and 
immunoblotting methods (Fig. 3). The 
level of MDR1 mRNA was significantly 
increased by treatment with oxaliplatin in 
a concentration dependent manner (Figs. 
3a and 3b). The level of MDR1 mRNA in 
LLC-PK1 cells treated with 10 µM 
oxaliplatin was ca. 2.5-fold higher than 
that in the control. Immunoblotting also 
indicated that MDR1 expression was 
about 5-fold higher in LLC-PK1 cells 
control (Fig. 3c). 
 
DISC
 
with oxaliplatin
te
effects of paclitaxel, a substrate of MDR1, 
in LLC-PK1 cells, presumably by 
accelerating the functions of MDR1 
(Table 1). This phenomenon was also 
obtained in a previous study on cisplatin 
(Takara et al., 2003a). Therefore, the 
transport function and expression of 
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MDR1 was examined. The uptake of 
Rhodamine123, another substrate of 
MDR1, was significantly and 
concentration-dependently reduced (Fig. 
1), and the efflux of Rhodamine123 from 
LLC-PK1 cells was significantly enhanced 
by pretreatment with oxaliplatin for 48 h 
(Fig. 2). These experiments suggest an 
acceleration of the transport function of 
MDR1 on pretreatment with oxaliplatin. 
In addition, these accelerated functions 
were supported by the suppression of 
Rhodamine123’s transport by a 
representative MDR1 substrate/inhibitor, 
ciclosporin (CsA) (Table 2 and Fig. 2). As 
with cisplatin, exposure to oxaliplatin for 
48 h resulted in an increase in the 
expression of MDR1 as detected using 
RT-PCR and immunoblotting (Fig. 3). 
Collectively, the present findings 
suggested that exposure for 48 h to 
oxaliplatin caused the up-regulation of 
MDR1 function and expression in 
LLC-PK1 cells, being similar to the 
previous report concerning cisplatin, a 
nephrotoxic anticancer drug (Demeule et 
al., 1999; Huang et al., 2001; Takara et al., 
2003a). Although oxaliplatin is less 
nephrotoxic than cisplatin, some reports 
have described renal dysfunction after the 
administration of oxaliplatin. Pinotti et al. 
documented a case of acute tubular 
necrosis due to oxaliplatin (Pinotti and 
Martinelli 2002). In addition, Labaye et al. 
reported that the spectrum of side effects 
from oxaliplatin included reversible acute 
renal failure with tubular necrosis (Labaye 
et al., 2005). Therefore, the up-regulation 
of MDR1 expression was considered to 
provide protection against the cytotoxic 
effects of oxaliplatin. Regrettably, the 
relationship between the change in the 
expression of MDR1 and nephrotoxic 
intensity could not be entirely explained. 
 
Recently, MDR1 has attracted attention as 
e regulatory factor for maintaining th
homeostasis and the induction of 
apoptosis (Huang et al., 2001; Johnstone 
et al., 2000; Sakaeda et al., 2002; Smyth et 
al., 1998). Huang et al. assessed 
cisplatin-induced nephrotoxicity using a 
microarray, and demonstrated that 
cisplatin-treatment for 7 days induced the 
expression of MDR1 and proapoptotic 
proteins, i.e., annexin V, Bax, and 
Gadd153 (Huang et al., 2001). In addition, 
MDR1 was demonstrated to confer 
long-term resistance to caspase-dependent 
apoptotic stimuli (Johnstone et al., 2000). 
On the other hand, the expression of 
MDR1 was also demonstrated to be 
up-regulated by apoptotic stimuli, 
resulting in the suppression of apoptotic 
signaling presumably via the 
mitochondrial pathway (Sakaeda et al., 
2002). Therefore, MDR1 is considered to 
have the ability to control and maintain 
normal conditions, and thus the present 
findings may represent one of the 
protective mechanisms via the apoptotic 
pathway against cell injury by anticancer 
drugs. In fact, it was reported that 
oxaliplatin apparently reduced the 
expression of apoptosis-inhibitory factors, 
and phosphorylation of Bcl-2 and Bcl-xl 
as early as 24 h after treatment, although it 
did not change the expression of Bax 
(Fujie et al., 2005). 
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In clinical practice, oxaliplatin has been 
equently used in combination with 
dings 
ggested that transient exposure to 
as 
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f transmembrane drug efflux as a mechanism 
assidy J, Misset JL. Oxaliplatin-related side 
, Brossard M, Beliveau R. 
on of 
-glycoprotein and canalicular multispecific 
akih MG. 5-fluorouracil leucovorin and 
fr
5-fluorouracil and levofolinate according 
to the FOLFOX protocol (de Gramont et 
al., 2000; Fakih 2004). A standard clinical 
dose of oxaliplatin in the FOLFOX 
protocol is 85-100 mg/m2 delivered by 
infusion, and the mean maximum plasma 
concentration after dosing at 85 mg/m2 
over 2 h ranged from 0.587 to 1.563 
µg/mL as free platinum (ca. 3 to 8 µM as 
platinum) (Kho et al., 2006). The 
concentration of oxaliplatin used in the 
present study was 10 µM at maximum. 
This was not very different from an 
achievable plasma concentration in 
patients receiving standard dosages of 
oxaliplatin, and thus the present findings 
may apply to the clinical situations. 
 
In conclusion, the present fin
su
oxaliplatin up-regulated the function and 
expression of MDR1 in the porcine kidney 
epithelial cell line LLC-PK1. The results 
were comparable to those for cisplatin, 
although there was a difference in 
nephrotoxic intensity. The present study 
will provide valuable information for 
developing a more effective and safer 
cancer chemotherapy with oxaliplatin. 
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